Brief: Pulmatrix Expects To Initiate New Phase 2B Clinical Study Of Pulmazole, Which Would Be Of Longer Duration And Include Efficacy Primary Endpoints

Pulmatrix

13/07/2020 13:55

July 13 (Reuters) - Pulmatrix Inc  PULM.O :
    * PULMATRIX - EXPECTS TO INITIATE NEW PHASE 2B CLINICAL
STUDY OF
OF PULMAZOLE, WHICH WOULD BE OF LONGER DURATION AND INCLUDE
EFFICACY PRIMARY ENDPOINTS
    * PULMATRIX - THERE CAN BE NO ASSURANCE CO WILL BE ABLE TO
RENEGOTIATE DEVELOPMENT, COMMERCIALIZATION AGREEMENT WITH CIPLA
ON FAVORABLE TERMS, OR AT ALL

Source text: [https://bit.ly/3fqqUN8]
Further company coverage:  PULM.O 

 (Reuters.Briefs@thomsonreuters.com)